Lincoln Pharmaceuticals Limited
Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India. The company offers products in the areas of anticold, antibiotic, otolaryngology, pain management, gastro, anti-malarial, anti-fungal, corticosteroids and cosmo-derma, anti-diabetic, anti-hypertensive, gynecology, cardio and CNS, respiratory system, and dyslipidemic; and branded generics. It … Read more
Market Cap & Net Worth: Lincoln Pharmaceuticals Limited (LINCOLN)
Lincoln Pharmaceuticals Limited (NSE:LINCOLN) has a market capitalization of $142.85 Million (₹12.37 Billion) as of March 18, 2026. Listed on the NSE stock exchange, this India-based company holds position #20059 globally and #1021 in its home market, demonstrating a -0.14% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lincoln Pharmaceuticals Limited's stock price ₹617.65 by its total outstanding shares 20029728 (20.03 Million).
Lincoln Pharmaceuticals Limited Market Cap History: 2015 to 2026
Lincoln Pharmaceuticals Limited's market capitalization history from 2015 to 2026. Data shows growth from $54.44 Million to $142.85 Million (11.21% CAGR).
Lincoln Pharmaceuticals Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lincoln Pharmaceuticals Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.02x
Lincoln Pharmaceuticals Limited's market cap is 0.02 times its annual revenue
1.01x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.14x
Lincoln Pharmaceuticals Limited's market cap is 0.14 times its annual earnings
10.29x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $41.12 Million | $4.00 Billion | $236.82 Million | 0.01x | 0.17x |
| 2017 | $52.76 Million | $3.50 Billion | $281.23 Million | 0.02x | 0.19x |
| 2018 | $50.27 Million | $3.55 Billion | $346.23 Million | 0.01x | 0.15x |
| 2019 | $46.34 Million | $3.57 Billion | $487.10 Million | 0.01x | 0.10x |
| 2020 | $55.44 Million | $3.77 Billion | $514.39 Million | 0.01x | 0.11x |
| 2021 | $82.01 Million | $4.15 Billion | $622.50 Million | 0.02x | 0.13x |
| 2022 | $81.80 Million | $4.68 Billion | $693.55 Million | 0.02x | 0.12x |
| 2023 | $140.64 Million | $5.05 Billion | $728.99 Million | 0.03x | 0.19x |
| 2024 | $182.20 Million | $5.81 Billion | $933.05 Million | 0.03x | 0.20x |
| 2025 | $111.93 Million | $6.23 Billion | $823.46 Million | 0.02x | 0.14x |
Competitor Companies of LINCOLN by Market Capitalization
Companies near Lincoln Pharmaceuticals Limited in the global market cap rankings as of March 18, 2026.
Key companies related to Lincoln Pharmaceuticals Limited by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Lincoln Pharmaceuticals Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Lincoln Pharmaceuticals Limited's market cap moved from $54.44 Million to $ 142.85 Million, with a yearly change of 11.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₹142.85 Million | +27.63% |
| 2025 | ₹111.93 Million | -38.57% |
| 2024 | ₹182.20 Million | +29.56% |
| 2023 | ₹140.64 Million | +71.92% |
| 2022 | ₹81.80 Million | -0.26% |
| 2021 | ₹82.01 Million | +47.93% |
| 2020 | ₹55.44 Million | +19.65% |
| 2019 | ₹46.34 Million | -7.82% |
| 2018 | ₹50.27 Million | -4.73% |
| 2017 | ₹52.76 Million | +28.30% |
| 2016 | ₹41.12 Million | -24.47% |
| 2015 | ₹54.44 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Lincoln Pharmaceuticals Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $142.85 Million USD |
| MoneyControl | $142.85 Million USD |
| MarketWatch | $142.85 Million USD |
| marketcap.company | $142.85 Million USD |
| Reuters | $142.85 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.